{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:16:25Z","timestamp":1786119385259,"version":"build-2736575974"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1097\/md.0000000000003753","type":"journal-article","created":{"date-parts":[[2016,5,26]],"date-time":"2016-05-26T11:07:09Z","timestamp":1464260829000},"page":"e3753","source":"Crossref","is-referenced-by-count":19,"title":["Effectiveness of 18F-FDG-PET\/CT vs Bone Scintigraphy in Treatment Response Assessment of Bone Metastases in Breast Cancer"],"prefix":"10.1097","volume":"95","author":[{"given":"Kusai M.","family":"Al-Muqbel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami J.","family":"Yaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-35-20210226","doi-asserted-by":"crossref","first-page":"55S","DOI":"10.2967\/jnumed.108.057240","article-title":"Response to therapy in breast cancer","volume":"50","author":"Avril","year":"2009","journal-title":"J Nucl Med"},{"key":"R3-35-20210226","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1093\/annonc\/mdq343","article-title":"Positron emission tomography\/computed tomography in the management of recurrent\/metastatic breast cancer: a large retrospective study from the Royal Marsden Hospital","volume":"22","author":"Constantinidou","year":"2011","journal-title":"Ann Oncol"},{"key":"R4-35-20210226","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10549-006-9435-1","article-title":"Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP)","volume":"105","author":"Specht","year":"2007","journal-title":"Breast Cancer Res Treat"},{"key":"R5-35-20210226","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S1076-6332(03)80461-0","article-title":"Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy","volume":"9","author":"Stafford","year":"2002","journal-title":"Acad Radiol"},{"key":"R6-35-20210226","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1200\/JCO.2007.11.2854","article-title":"Fusion of metabolic function and morphology: sequential [18F]fluorodeoxyglucose positron-emission tomography\/computed tomography studies yield new insights into the natural history of bone metastases in breast cancer","volume":"25","author":"Du","year":"2007","journal-title":"J Clin Oncol"},{"key":"R7-35-20210226","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","article-title":"Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group","volume":"35","author":"Young","year":"1999","journal-title":"Eur J Cancer"},{"key":"R8-35-20210226","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1093\/annonc\/mdu558","article-title":"Assessing response to treatment of bone metastases from breast cancer: what should be the standard of care?","volume":"26","author":"Woolf","year":"2015","journal-title":"Ann Oncol"},{"key":"R9-35-20210226","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00432-002-0342-5","article-title":"Comparing whole body (18)F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer","volume":"128","author":"Yang","year":"2002","journal-title":"J Cancer Res Clin Oncol"},{"key":"R10-35-20210226","first-page":"499","article-title":"Bone scintigraphy in the monitoring of treatment effect of bisphosphonates in bone metastatic breast cancer","volume":"11","author":"Chavdarova","year":"2006","journal-title":"J BUON"},{"key":"R11-35-20210226","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s12149-012-0595-2","article-title":"Evaluation of sequential FDG-PET\/CT for monitoring bone metastasis of breast cancer during therapy: correlation between morphological and metabolic changes with tumor markers","volume":"26","author":"Katayama","year":"2012","journal-title":"Ann Nucl Med"},{"key":"R12-35-20210226","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1148\/radiol.2471070567","article-title":"Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET\/CT","volume":"247","author":"Tateishi","year":"2008","journal-title":"Radiology"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000003753","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:10:25Z","timestamp":1786039825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00005792-201605240-00035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":11,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000003753","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]}}}